Inhibition of apoptotic Bax translocation to the mitochondria is a central function of parkin by Charan, R A et al.
 
Inhibition of apoptotic Bax translocation to the mitochondria is a
central function of parkin
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Charan, R A, B N Johnson, S Zaganelli, J D Nardozzi, and M J
LaVoie. 2014. “Inhibition of apoptotic Bax translocation to the
mitochondria is a central function of parkin.” Cell Death &
Disease 5 (7): e1313. doi:10.1038/cddis.2014.278.
http://dx.doi.org/10.1038/cddis.2014.278.
Published Version doi:10.1038/cddis.2014.278
Accessed February 16, 2015 9:32:14 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785979
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAOPEN
Inhibition of apoptotic Bax translocation to the





1,2 and MJ LaVoie*
,1,2
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, affecting 1–3% of the population over 65.
MutationsintheubiquitinE3ligaseparkinarethemostcommoncauseofautosomalrecessivePD.Theparkinproteinpossesses
potent cell-protective properties and has been mechanistically linked to both the regulation of apoptosis and the turnover of
damaged mitochondria. Here, we explored these two functions of parkin and the relative scale of these processes in various cell
types. While biochemical analyses and subcellular fractionation were sufﬁcient to observe robust parkin-dependent mitophagy
in immortalized cells, higher resolution techniques appear to be required for primary culture systems. These approaches,
however, did afﬁrm a critical role for parkin inthe regulation of apoptosis in primary cultured neurons and all other cells studied.
Our prior work demonstrated that parkin-dependent ubiquitination of endogenous Bax inhibits its mitochondrial translocation
and can account for the anti-apoptotic effects of parkin. Having found a central role for parkin in the regulation of apoptosis, we
further investigated the parkin-Bax interaction. We observed that the BH3 domain of Bax is critical for its recognition by parkin,
andidentiﬁedtwolysinesthatarecrucialforparkin-dependentregulationofBaxtranslocation.Last,adisease-linkedmutationin
parkin failed to inﬂuence Bax translocation to mitochondria after apoptotic stress. Taken together, our data suggest that
regulation of apoptosis by the inhibition of Bax translocation is a prevalent physiological function of parkin regardless of the
kind of cell stress, preventing overt cell death and supporting cell viability during mitochondrial injury and repair.
Cell Death and Disease (2014) 5, e1313; doi:10.1038/cddis.2014.278; published online 3 July 2014
Loss-of-functionmutationsintheubiquitinE3ligaseparkinare
the most common cause of autosomal recessive Parkinson’s
disease (PD).
1 Multiple functions have been ascribed to
parkin, most notably the inhibition of apoptosis
2–7 and
the induction of autophagic mitochondrial turnover (mito-
phagy).
8,9 However, the relative scale of these effects
mediated by endogenous parkin and whether these
processes can occur concomitantly or are mutually exclusive,
is not known.
Bax is a primary effector of cell death that translocates from
thecytosoltothemitochondriauponstress,whereitfacilitates
cytochrome c release and the subsequent caspase
cascade.
10WepreviouslyidentiﬁedBaxasaparkinsubstrate,
and found that the anti-apoptotic effects of parkin can be
directly linked to the parkin-dependent ubiquitination of Bax
and inhibition of its mitochondrial translocation.
3 Recent
corroborative evidence showed that primary cultured neurons
from parkin knock-out (KO) mice accumulate greater levels of
activated Bax at the mitochondria than wild-type (WT)
neurons after apoptotic stimulation,
11 while a separate report
showed the parkin-dependent ubiquitination of Bax during
mitophagy.
12
In addition to its anti-apoptotic function, parkin facilitates a
depolarization-induced and autophagy-dependent turnover of
mitochondria. This process is robustly observed in immorta-
lized cell lines expressing human parkin, where exposure to
the mitochondrial depolarizing agent carbonyl cyanide
3-chlorophenylhydrazone (CCCP) causes rapid recruitment
of parkin from the cytosol to the mitochondrial outer
membrane and a coordinated proteasome and auto-
phagosome-mediated turnover of the entire organelle.
8,13–15
Examination of this process in primary neuronal cultures
with endogenous parkin expression, however, has been
challenging,
16–19 and a cooperative role for inhibition of
mitochondria-dependent cell death has not been investigated
in the context of mitophagy.
In this study, we sought further insight into the biological
functions of parkin across multiple cell types. Our data
showed that whole-cell biochemical techniques were not
sufﬁcient to observe the participation of endogenous parkin in
mitochondrial turnover but were able to conﬁrm the parkin-
dependent regulation of apoptosis. Further examination of the
parkin-dependent regulation of apoptosis identiﬁed two
speciﬁc lysines of Bax that are critical for recognition and
inhibition of its translocation to the mitochondria by parkin.
In addition, the BH3 domain of Bax was critical for its association
with parkin. Importantly, we observed parkin-dependent
mitophagy and inhibition of apoptotic Bax translocation in
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pathways coexist and likely cooperate within neurons. Taken
together, our data indicate that the parkin-dependent regula-
tion of Bax is critical for cell survival, irrespective of the nature
of cell stress involved.
Results
Roles of endogenous parkin in brain-derived primary
cells. We and others have shown that endogenous parkin
has an important role in the neuronal regulation of
apoptosis.
3,11,20 However, we had not examined the
response of endogenous parkin in these cells to induction
of mitophagy. Primary cortical neurons from E18 WT and
parkin KO mice were treated with vehicle, CCCP (10mM,
24h), or staurosporine (300nM, 5h). Isolation of cytosolic
and mitochondrial fractions revealed that neither treatment
induced robust mitochondrial translocation of parkin
(Figures 1a and b). Outer mitochondrial membrane proteins
voltage-dependent anion channel (VDAC) and translocase of
outer membrane 20 (TOM20) were unaffected, indicating
these biochemical measures were insufﬁcient to resolve
CCCP-induced mitophagy (Figure 1b). Staurosporine treat-
ment increased the apoptotic markers cleaved caspase-3
and cleaved poly ADP ribose polymerase (PARP) in
cytosolic fractions of both cultures, however, they were
substantially elevated in parkin KO neurons compared with
WT (Figure 1a), as expected.
2,3 Interestingly, 24-h exposure
to CCCP also resulted in evidence of apoptosis in both WT
and parkin KO neurons, and while there were subtle
differences between WT and KO neurons, these were not
statistically signiﬁcant. To consider species-speciﬁc differ-
ences, we also examined WT rat primary cortical neurons.
Apoptotic stress (300nM, 5h) or CCCP (10mM, 24h) did not
induce quantiﬁable mitochondrial translocation of parkin and
showed a trend for decreased TOM20 that was not
statistically signiﬁcant, while both treatments also increased
apoptotic markers (Figures 1c and d). To study an additional
brain resident cell that expresses endogenous parkin, we
isolated primary astrocytes from WT neonatal mice and
assessed the behavior of parkin during mitochondrial stress.
We failed to detect mitochondrial translocation of parkin or
the turnover of mitochondrial proteins following 6 or 24h of
CCCP treatment (Figures 2a and b). We did observe a
time-dependent decrease in parkin levels in the cytosolic
fractions, possibly due to stress-induced turnover, decreased
parkin solubility or cell death (Figure 2a).
Scale of CCCP-induced parkin-mediated mitophagy
varies by cell type. Our inability to resolve mitophagy using
biochemical techniques in neurons and astrocytes led us to
speculate that the proportion of the mitochondrial network
turned over during CCCP-induced mitophagy might differ
across cell types. We ﬁrst assessed MES neural cell lines,
originally derived from the dopaminergic neurons of the rat
substantia nigra displaying dopaminergic properties and
expressing low levels of endogenous parkin.
21,22 MES cells
with or without stable overexpression of WT human
parkin were treated with vehicle or 20mM CCCP for 24h.
In whole-cell lysates we did not observe robust CCCP-induced
changes in the levels of outer mitochondrial proteins (VDAC,
TOM20) or the inner mitochondrial membrane proteins
(SHDA (member of Complex II) and ATP5A (member of
Complex V)), regardless of parkin expression (Figure 3a).
However, the same treatment of human embryonic kidney
293 (HEK) cells which also express low endogenous parkin
23
with stable parkin expression (HEK-Parkin) revealed a
signiﬁcant reduction in several (but not all) markers of
mitochondrial content in the whole-cell lysates of HEK-
Parkin, but not HEK cells (Figure 3b), demonstrating a more
pronounced mitophagy in this cell type. It is unclear why
ATP5A was not reduced in HEK-Parkin cells, as premature
time points, selective mitochondrial protein degradation
24,25
or other mechanisms may be responsible.
Next, we analyzed mitochondrial fractions of MES, HEK
and Chinese hamster ovary (CHO) cells with or without stable
parkin overexpression at 4 or 24h. In MES-Parkin cells,
we did not observe mitochondrial translocation of parkin at
either time points (Figure 3c). In fact, mitochondrial levels of
parkin were reduced after CCCP treatment, consistent with
observations in the primary neuronal and astrocyte cultures
(Figures 1d and 2a). However, when analyzing isolated
mitochondrial fractions, a subtle and signiﬁcant decrease in
TOM20 and VDAC was observed in MES-Parkin cells
(Figure 3c) that was not resolved at the whole-cell level
(Figure 3a), indicative of a mitophagic response in these
neural cells comparableto the subtle loss of TOM20 observed
in rat primary cortical neurons. Mitochondrial fractions from
HEK-Parkin and CHO-Parkin cells, however, displayed a
more robust response. We observed translocation of
parkin to the mitochondria after 4h of CCCP treatment
(Figures 3d and e), and reduction in TOM20 and VDAC as
early as 4h post treatment. In fact, these markers were
virtually absent at 24h (Figures 3d and e), suggesting
complete mitochondrial turnover in these cells.
26
Regulations of Bax and mitochondrial turnover are not
mutually exclusive functions of parkin. We previously
described the ubiquitination and regulation of endogenous
Bax by parkin in neural MES cells and primary cultured
neurons.
3 Given that the scale of mitophagy appeared
different across various cell types, we considered whether
mitophagy is preferentially manifested in some cell types and
the inhibition of Bax translocation in others. In the
HEK-Parkin cell line that displayed the most robust mito-
phagy, the levels of Bax in whole-cell lysates were also
dramatically reduced by parkin (Figure 4a), suggesting that
the participation of one parkin function does not preclude the
other. Next, we treated HEK and HEK-Parkin cells with
vehicle or the proteasomal inhibitor MG-132 (10mM, 6h), and
probed for levels of ubiquitinated Bax by immunoprecipitation
(IP)–Western blot. In the absence of MG-132 we did not
detect ubiquitinated Bax (Figures 4b and d), however,
MG-132 treatment allowed for detection of endogenous
ubiquitinated Bax, which was substantially increased by
parkin expression (Figures 4c and d). We then isolated two
monoclonal parkin-expressing lines from the polyclonal pool
with differential parkin expression, named clones M1 and M2
(Figure 4e). We not only conﬁrmed a gene-dose response for
the effects of parkin on whole-cell Bax levels (Figure 4e) but
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Cell Death and Diseasealso for the levels of ubiquitinated Bax in these respective
lines (Figures 4f and g).
Prior studies have suggested that parkin may have a role in
gene transcription.
27–29 Given the large effect on endogenous
Bax by parkin, we measured the mRNA levels of Bax by
qPCR, using the HEK-ParkinM2 clone that expressed the
highest levels of parkin and had the greatest effect on Bax
protein levels. Despite the dramatic changes in Bax protein,
we found no change in Bax mRNA levels when normalized to
GAPDH (Figure 4h).
Figure 1 Primary brain-derived cells demonstrate a muted mitophagic response, but show a parkin-dependent sensitivity to apoptosis. Mouse or rat primary cortical
neuronsisolatedat E18weretreatedwith 300nMstaurosporineor10mM carbonylcyanide-3-chlorophenylhydrazone(CCCP)forstatedtimes.(a)CytosolicfractionsfromWT
or parkin KO mouse cortical neurons were treated with DMSO, staurosporine (Sts) for 6h or CCCP for 24h and probed for parkin and apoptotic markers, and (b) the
mitochondrial fractions were analyzed for mitochondrial protein levels. Hash (#) indicates a non-speciﬁc band. For quantiﬁcation, band intensities of proteins in the cytosolic
fractions were normalized to WT, and the mitochondrial proteins were normalized to the control (DMSO). (c) WT rat cortical neurons were treated with DMSO, CCCP or
staurosporine for times listed and probed for parkin, apoptotic markers and (d) mitochondrial proteins. For quantiﬁcation, band intensities of proteins from cytosolic and
mitochondrial fractions were normalized to vehicle (DMSO). All bars represent mean±S.E.M., n¼3. Asterisks indicate signiﬁcant differences compared with WT or control
(Po0.05)
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Cell Death and DiseaseThe BH3 domain of Bax is required for its interaction
with parkin. Having conﬁrmed the potent effect of parkin
on Bax at the protein level, we sought new insights into the
nature of their physical interaction. Mutagenesis and
truncation/deletions of parkin often lead to its misfolding
and insolubility,
30 hence we focused on subtle modiﬁca-
tions of Bax. The BH3 domain of Bax is required for its
pro-apoptotic properties,
31 and other putative substrates of
parkin (Nix, Bcl-2) also contain this motif.
32,33 Thus, we
hypothesized that this domain is important for parkin–Bax
interactions. Since Bcl-xl does not interact with parkin in
mammalian cells,
32 we swapped the full a-helix 2 of Bax
containing the BH3 domain with the complete a-helix 2
of the anti-apoptotic Bcl-xl containing its BH3 domain (Bax-
BH3
sw)i na ne f f o r tt op r e s e r v ep r o p e rf o l d i n g( F i g u r e5 a ) .
We then assessed if this replacement affected parkin
binding. Catalytically inactive E3 ligase mutants are known
to bind their substrates more avidly than their active
forms,
3,34 t h u s ,w ea n a l y z e dW Tp a r k i na l o n gw i t ha
PD-linked missense mutation (R275W) and a premature
termination (W453X). HEK cells were co-transfected to
express one of the parkin variants along with either Flag-
tagged WT Bax or Bax-BH3
sw and the two proteins were
co-IPed. We observed comparable levels of parkin expres-
sion and pulldown across all conditions for WT and R275W
mutant, while the W453X mutation was not well expressed
or IPed (Figure 5b), as described earlier.
35,36 We observed
that WT Bax interacted with WT parkin, and that the
PD-linked loss-of-function mutant R275W pulled down
more WT Bax despite a comparable parkin IP (Figure 5b),
as previously described.
3 However, the interaction between
parkin and Bax was lost in all cases when the BH3 domain of
Bax was replaced (Figure 5b).
Two lysines are required for inhibition of mitochondrial
Bax translocation by parkin. Prior work demonstrated that
the parkin-dependent regulation of Bax was dependent on
the availability of lysines within Bax.
3 The BH3 domain of Bax
is important for parkin recognition (Figure 5), and its
secondary structure reveals that the sole lysine in this
domain (K64) is solvent exposed.
37 Additionally, a recent
study identiﬁed K21 on the N terminus of Bax to be
ubiquitinated by parkin upon CCCP-induced mitophagy.
12
Hence, we tested both K21 and K64 of Bax for their role in
parkin-dependent regulation of mitochondrial translocation.
Simultaneous mutation of all nine lysines residues of Bax
does not alter its apoptotic function,
3 thus we mutated K21
and/or K64 to arginines (K21R, K64R and K21R/K64R),
preserving charge and likely retaining Bax function.
In addition, co-IP analysis revealed that these lysine
mutations had no effect on the physical interaction with
parkin (Figure 5c).
Bax is known to translocate to the mitochondria to facilitate
apoptosis
38,39andwehaveobservedthisresponse,aswellas
the parkin-dependent inhibition of Bax translocation, in CHO
cells.
3 Therefore, we transiently transfected CHO cells
with GFP-tagged WT Bax or the mutants (K21R, K64R,
K21R/K64R), analyzed the lysates and conﬁrmed that the
engineered mutations did not affect Bax expression
(Figure 6a). The mitochondrial translocation of the expressed
Bax constructs was assessed by co-transfecting mito-
mCherry to label mitochondria prior to image analysis,
Figure 2 Subcellular fractionation does not reveal a robust mitophagic response to CCCP in primary cultured murine astrocytes. (a) WT mouse astrocytes isolated from
P1–P4miceweretreatedwitheitherDMSOor20mMCCCPfor 6or24handlysatesfromcytosolicandmitochondrialfractionswereprobedforparkinandapoptoticmarkers,
and mitochondrial protein levels. (b) For quantiﬁcation, band intensities of proteins from mitochondrial fractions were normalized to vehicle (DMSO). All bars represent
mean±S.D., n¼3
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Cell Death and Diseaseas previously described.
3 Following treatment with vehicle or
staurosporine (1mM, 5h) to induce apoptosis, we classiﬁed
GFP-Bax localization as either (i) completely cytosolic,
(ii) predominantly cytosolic, (iii) predominantly mitochondrial
or (iv) completely mitochondrial (Figure 6b). In parental CHO
cells, staurosporine induced rapid translocation of all Bax
variants (Figure 6c) with the majority of cells displaying
complete mitochondrial translocation (Figure 6d). In CHO-
Parkincells,however,onlyWTBaxwasretainedinthecytosol
following the induction of apoptosis. Parkin expression was
associated with modest reductions in both the K21R
and K64R Bax translocation. The K21/K64 double mutant,
however, appeared completely unaffected by parkin
(Figures6candd).Forquantitativeassessmentandstatistical
analyses, we chose to pool the ‘predominant’ and ‘complete’
mitochondrial values to encompass all apoptotic Bax trans-
location. This grouping revealed that the lysine mutations had
no effect on Bax localization in the absence of stress, and this
was true in both the CHO and CHO-Parkin cell lines
(Figure 6e). We also conﬁrmed the potent parkin-dependent
inhibition ofWT Baxtranslocation,and theinability ofparkin to
prevent the translocation of the K21R/K64R Bax to the
mitochondria (Figure 6e). Moreover, there was a signiﬁcant
increase in the mitochondrial translocation of the K21R and
the K64R mutant as compared with WT Bax, suggesting a
partial loss of parkin recognition with each single mutation,
whereas the effect of the double mutant appeared to be
additive (Figure 6e).
Having identiﬁed two lysines critical for parkin-dependent
Bax inhibition, we asked whether these were sufﬁcient to
account for the totality of its parkin-dependent regulation. We
previously showed that a lysine-null Bax (ØK-Bax) retains its
full apoptotic function, but that the anti-apoptotic effect of
parkin is completely lost in cells that express this protein.
3
Figure3 Thescaleofparkin-mediatedmitophagyisaffectedbycelltype.DopaminergicMEScells(a),andHEKcells(b),eachwithorwithoutstableexpressionofparkin,
weretreated with either DMSO or 20mM CCCP for 24h in triplicate.Whole-cell lysateswere probedfor outer (VDAC andTOM20) andinner (ComplexII and V) mitochondrial
proteins to assess mitophagy. For quantiﬁcation, band intensities of proteins were normalized to vehicle (DMSO). (c) MES, (d) HEK and (e) CHO cells, with or without stable
expression of parkin, were treated with either DMSO or 20mM CCCP for 4 or 24h, and isolated mitochondrial fractions were probed for parkin translocation and for outer and
inner mitochondrial proteins to assess mitophagy. For quantiﬁcation, band intensities of proteins from mitochondrial fractions were normalized to vehicle (DMSO). All bars
represent mean±S.D., n¼3. Asterisks indicate signiﬁcant differences compared with control (Po0.05)
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Cell Death and DiseaseCHO and CHO-Parkin cells were transiently transfected with
untaggedWTBax,ØKBaxortheK21R/K64RBaxmutantand
treated with vehicle or staurosporine (1mM, 5h). Immuno-
cytochemistry with a human-speciﬁc Bax antibody was used
to score mitochondrial translocation. Parkin was unable to
preventmitochondrialtranslocationoftheK21R/K64Randthe
ØKBaxmutant,asopposedtotheWT Baxprotein,whichwas
retained in the cytosol in the presence of parkin (Figures 7a
and b). There no difference between the localization of the
double lysine mutant or the lysine-null Bax (Figure 7c),
suggesting that K21 and K64 are the sole lysines necessary
for parkin-dependent regulation of Bax.
A pathogenic loss-of-function mutation in parkin fails
to inhibit mitochondrial Bax translocation. There are
numerous disease-linked missense mutations in parkin but
many suffer from aggregation, instability and misfolding.
35,36
One mutation that has proven amenable for cell biological
experimentation is the really interesting new gene 1 (RING1)
domain mutant, R275W.
2,3,40 Therefore, WT and R275W-
parkin-stable CHO cells (Figure 8a) were transiently
co-transfected with GFP-tagged WT Bax and mito-mCherry.
Twenty-four hours later, cells were treated with vehicle or
staurosporine (1mM, 5h), and images were captured post
ﬁxation as described above. We observed the expected
retention of Bax in the cytoplasm of CHO-Parkin cells
following the induction of apoptosis. However, staurosporine
induced robust mitochondrial translocation of Bax in the
CHO-R275W cells (Figure 8b), despite the comparable
expression of this disease-linked mutant. Analysis of
Figure 4 Parkin-mediated regulation of Bax is cell-type independent. (a) Endogenous Bax expression in whole-cell lysates of HEK cells in a polyclonal line with stable
expression of parkin(HEK-Parkin).HEK andHEK-Parkin cells eitheruntreated (b) or treatedwith proteasomeinhibitor (MG-132, 10mM) for 6h (c). Following lysis, whole-cell
lysates and Bax IPs were probed by Western blot for ubiquitin. (d) Quantiﬁcation of IPed ubiquitin levels from (b) and (c) plotted as a percentage of control (HEK).
(e)EndogenousBaxexpressioninlysatesfromtwomonoclonallines(M1andM2)expressingdifferentiallevelsofparkin.(f)HEK,HEK-ParkinM1andHEK-ParkinM2cellswere
treatedwithproteasomeinhibitor(MG-132,10mM)for6h.Cellswerelysed,andwhole-celllysatesandBaxIPswereprobedbyWesternblotforubiquitin.(g)Quantiﬁcationof
IPed ubiquitin levels from b and c plotted as a percentage of control (HEK). (h) Quantitative RT-PCR was performed in HEK and HEK-ParkinM2 cells to assess Bax mRNA
levels. Graph is plotted as Bax mRNA levels normalized to control GAPDH mRNA levels. All bars represent mean±S.D., n¼3. Asterisks indicate signiﬁcant differences
compared with control (Po0.05)
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Cell Death and Diseaseendogenous Bax localization revealed that Bax was
predominantly at the mitochondria in cells expressing
R275W-parkin, whereas it was predominantly cytosolic even
after staurosporine treatment in the WT parkin cells
(Figure 8c). Statistical analyses of pooled mitochondrial
translocation conﬁrmed that WT parkin prevented Bax from
accumulating at the mitochondria, whereas the disease-
linked parkin mutant did not (Figure 8d).
Discussion
Here, we describe a varied scale of responses while studying
the role of PD-linked ubiquitin E3 ligase parkin in mitochon-
drial turnover across cell types. Data from multiple primary
cultured cells derived from brain suggested a more reﬁned
mitophagic response than the near complete loss of mito-
chondrial material observed in immortalized cell culture
systems, but a uniform regulation of Bax by parkin. HEK
and CHO cell lines overexpressing parkin showed robust
parkin-dependent mitophagy, as well as a potent inhibition of
the apoptotic translocation of Bax from the cytosol to the
mitochondria. Therefore,thesetwo pathwaysarenotmutually
exclusive rather parkin-dependent mitophagy, and the inhibi-
tion of Bax-dependent cell death coexist and likely cooperate
to maintain cell viability. We show for the ﬁrst time that parkin-
dependent regulation of Bax does not involve effects on
transcription, but rather requires the E3 ligase activity
of parkin and proteasomal degradation, as a pathogenic




myc-tagged wild-type parkin (WT) or mutant parkin (R275W and W453X). Whole-cell lysates were subjected to IP of parkin using a myc-tag antibody and whole-cell lysates
andIPswereprobedforBaxusingaFlag-tagantibodytovisualizeco-immunoprecipitationalongwithparkintodemonstratepulldown.(c)GFP-taggedWTorK21R/K64RBax
was transiently transfected in CHO cells stably expressing parkin (CHO-Parkin). Whole-cell lysates were subjected to IP using a parkin antibody, and starting lysates and IPs
were probed for Bax using a GFP antibody to visualize co-immunoprecipitation along with parkin to demonstrate pulldown. For quantiﬁcation, band intensities of WT and
mutant Bax were normalized to levels of parkin pulldown. All bars represent mean±S.D., n¼5
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Cell Death and Diseaseloss-of-function mutation could not regulate Bax. We also
found that two speciﬁc lysines in Bax are required for parkin-
mediated inhibition of its mitochondrial translocation.
The BH3 domain of Bax is important for its pro-apoptotic
function,
31,41 and we report that the domain is necessary for
its recognition by parkin. Since other cytosolic parkin
substrates (Bcl-2
32 and Nix
33) also possess BH3 domains,
thismayindicateacommonrecognitionmotifforparkin.Given
these data and the recently solved crystal structure of
parkin,
42–44 our new ﬁndings are likely to prove valuable in
future efforts to identify the structural requirement for
recognition of cytosolic parkin substrates, and may assist in
the identiﬁcation of new substrates.
Parkin-dependent ubiquitination of Bax is essential for the
inhibition of its apoptotic translocation to the mitochondria,
3
but the speciﬁc lysine residues involved were unknown.
Mutation of either K21 or K64 of Bax alone resulted in only a
modest reduction in parkin function; nonetheless, a combined
K21/K64 Bax mutant retains its ability to bind to parkin but not
subject to parkin-dependent inhibition. In fact, it behaved
identically to a previously characterized Bax construct devoid
of lysine resides,
3 thus, other lysine residues in Bax are likely
dispensable for parkin function. The K64 residue of Bax exists
within the BH3 domain and is solvent exposed,
45 while K21
within the N terminus is thought to be inaccessible under non-
apoptotic conditions.
39,46,47 Since apoptotic activation of Bax
results in a conformational change that exposes the N
terminus,
48 wespeculate thatunder non-apoptoticconditions,
parkin only partially retains Bax within the cytoplasm by
ubiquitinating thesole accessibleK64residue, consistentwith
Figure 6 Lysine 21 and 64 of Bax are required for parkin regulation of Bax translocation into the mitochondria. (a) Whole-cell lysates of CHO cells transiently expressing
wild-type human Bax (hBax) or each of its mutants and probed with the human-speciﬁc 2D2 antibody by Western blot. (b) Representative images of cells co-transfected with
mito-mCherry (mitochondrial marker) and GFP-Bax, showing the various stages of Bax translocation into the mitochondria after treatment with 1mM staurosporine for 5h.
Scale bar, 10mm. (c) CHO cells without or with stable expression of parkin (CHO-Parkin) were transiently transfected with wild-type GFP-Bax or each of its GFP-tagged
mutants. Representative images of cells showing Bax translocation into the mitochondria after treatment with DMSO or 1mM staurosporine (Sts) for 5h. Scale bar, 20mm.
(d) Quantiﬁcation of b. Cells were scored visually for Bax translocation into the mitochondria as completely cytoplasmic (open), predominantly cytoplasmic (open dotted),
predominantly mitochondrial (gray) or completely mitochondrial (gray dotted) by a blinded observer. Hundred and ﬁve to 160 cells were counted per condition. Data were
plotted from three independent experiments. (e) Percentage of pooled mitochondrial fractions (predominantly mitochondrialþcompletely mitochondrial) plotted from d. All
bars represent mean±S.D., n¼3. Asterisk indicates signiﬁcant differences when compared with WT, # indicates signiﬁcant difference between K21R and K21R/K64R,
w indicates signiﬁcant difference between K64R and K21R/K64R (Po0.05)
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Cell Death and DiseaseFigure 7 K21 and K64 are necessary and sufﬁcient for parkin-regulated Bax translocation to the mitochondria. (a) CHO cells without or with stable expression of parkin
(CHO-Parkin)weretransientlytransfectedwithuntaggedwild-type(WT)Bax,Baxwithnolysines(ØKBax)andK21R/K64RBax.Representativeimmunocytochemicalimages
ofcellsshowingBaxtranslocationintothemitochondria(humanBax-speciﬁc2D2antibody)andafterDAPItreatmentwith1mMstaurosporine(Sts)for5h(b)Quantiﬁcationof
a. Cells were scored visually for Bax translocation into the mitochondria as completely cytoplasmic (open), predominantly cytoplasmic (open dotted), predominantly
mitochondrial (gray) or completely mitochondrial (gray dotted) by a blinded observer. Sixty-six to 102 cells were counted per condition. Data plotted from 3 independent
experiments. (c) Percentage of pooled mitochondrial fractions (predominantly mitochondrialþcompletely mitochondrial) plotted from b. All bars represent mean±S.D.,
n¼3. Asterisks indicate signiﬁcant differences when compared with WT, n.s. indicates not signiﬁcant (Po0.05)
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Cell Death and Diseaseparkin-dependent ubiquitination of Bax in the absence of
apoptotic stimulation (Figure 4).
3 However, stress-induced
conformational changes in Bax would result in access to both
K64 and K21, allowing parkin to potentially inhibit Bax
translocation to the mitochondria and promote cell survival.
There is a potential adaptive advantage to this proposed
two-tieredregulationofBaxbyparkin.Recentstudiessuggest
that members of the Bcl-2 family may have critical cellular
roles to play beyond programmed cell death (for review,
see Hardwick and Soane
49). Bax is thought to play a role
in supporting bioenergetics, the mitochondrial network
50
and in synaptic transmission. and long-term depression.
51
These processes may require physiological levels of Bax at
the mitochondria. In our model, parkin can only partially
regulate the mitochondrial localization of Bax under normal
conditions, where the N terminus is inaccessible, whereas the
apoptotic conformation of Bax would be robustly affected by
parkin under more pathologic conditions. Future experiments
may distinguish the roles of parkin in modulating physiological
and pathological functions of Bax, and determine whether this
model also applies to other E3 ligases that regulate Bax.
52
Thereis anopen debate regardingthe role ofapoptosisand
Bcl-2-related proteins such as Bax in adult-onset neuro-
degenerative disease, such as PD.
53 For example, Bax was
shown to accumulate in nigral neurons from postmortem
samples taken from individuals with PD in one study,
54 but not
in another.
55 However, Bax-rich inclusions in PD brain have been
reported.
56,57 Also, MPTP-induced neurotoxicity is associated
with mitochondrial Bax accumulation in vivo, and Bax KO mice
are resistant in this PD model.
58 Other members of the Bcl-2
family such as Nix, PUMA, Bak and Bim have also been
implicated in in vitro and in vivo models of PD.
57,59–61 Thus, our
data may implicate deﬁcits in the parkin-dependent regulation
of Bax as a contributing factor to the neuronal loss in PD.
Mitophagy has been well-documented by numerous groups
in several immortalized cell lines overexpressing parkin.
8,62
However,thenatureofthisprocessinneurons,whichexpress
endogenous parkin, has been somewhat controversial.
16,19,63
Our data suggest that the scale of mitochondrial turnover in
primary cells expressing endogenous parkin may be relatively
muted when compared with cancer cell lines overexpressing
human parkin. This was evident in our studies where
mitophagy was readily observed in HEK cells at the whole-
cell level, but only following subcellular fractionation in neural
MEScells.Subcellularfractionation,inturn,wasinsufﬁcientto
observe mitophagy in primary neurons. Therefore, higher
resolution techniques may be required to examine neuronal
mitophagy. Phenotypic differences in parkin mitophagy
across different cell lines may be due to the unique
bioenergetics of each model system,
19 differential expression
of competing deubiquitinating enzymes, PINK1 expression
levels, the time points chosen for our studies or other as yet
unidentiﬁed cofactors. Nonetheless, we have established the
role of cytosolic endogenous parkin in the ubiquitination
of endogenous Bax in neurons
3 and in regulation of
apoptosis,
2,4,7 and now we demonstrate the coexistence of
Figure 8 Disease-associated mutation of parkin is unable to regulate Bax translocation to the mitochondria. (a) Lysates from CHO cells stably expressing WT parkin or
mutant R275W-parkin. (b) CHO cells expressing WT or R275W Parkin were transiently transfected with WT GFP-Bax and the mitochondrial marker mito-mCherry.
Representativeimagesof ﬁxedcellsshowinglocalizationofGFP-BaxaftertreatmentwithDMSO or1mM staurosporine (Sts)for 5h.Scalebar,20mm. (c) Quantiﬁcationof b.
Cells were scored as described in Figure 5. Forty-six to 64 cells were counted per condition. Data plotted from three independent experiments. (d) Percentage of pooled
mitochondrial fractions (predominantly mitochondrialþcompletely mitochondrial) plotted from b. All bars represent mean±S.D., n¼3. Asterisk indicates signiﬁcant
difference when compared with WT (Po0.05).
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Cell Death and Diseaseboth parkin-dependent regulation of Bax and mitochondrial
turnover pathways within the same cells. This raises the
possibility that the inhibition of Bax-dependent cell death by
cytosolic parkin provides the opportunity for mitochondrially
recruited parkin to mediate mitophagy and recovery following
cell injury. The pro-survival effects of cytosolic parkin during
the induction of selective mitophagy by the translocated
parkin may be particularly critical for the maintenance of post-
mitotic cell types such as neurons, and partially explain the
unique neuropathological consequences of parkin deﬁciency
in humans.
Materials and Methods
Cell culture, plasmids and transfection methods. All cell culture and
transfection methods have been previously described.
2,3,21,22 Codon optimized
WT human Bax and engineered mutant human Bax with the BH3 domain
swapped for the BH3 domain of Bcl-xl (Bax-BH3
sw) were synthesized and
subcloned into pcDNA3.3 vector with the addition of a FLAG tag by GeneArt
(Life Technologies, Grand Island, NY, USA). Mutant human Bax protein with all
lysines replaced with arginines (Bax |-Lys) was engineered by GenScript
(Piscataway, NJ, USA) and subcloned into pcDNA 3.1(þ) vector (Invitrogen,
Grand Island, NY, USA).
3 WT GFP-Bax was a kind gift from Dr Richard Youle
(NIH, NINDS, Bethesda, MD, USA). Mutations in WT GFP-Bax at lysine 21, lysine
64 or both lysines 21 and 64 replaced with arginines (K21R, K64R and K21R/
K64R, respectively) were engineered using site-directed mutagenesis. Primers for
K21R: Forward, 50-gctctgagcagatcatgaggacaggggcccttttgc-30; Reverse, 50-gcaaa
agggcccctgtcctcatgatctgctcagagc-30. Primers for K64R: Forward, 50-gcgagtgtctc
aggcgcatcggggacgaactgg-30; Reverse, 50-cgtccccgatgcgcctgagacactcgctcagc-30.
The K21R/K64R double mutant was generated sequentially using the same primers.
Antibodies and reagents. Antibodies used for Western blotting were parkin
(PRK8; sc-32282; Santa Cruz Biotechnology, Santa Cruz, CA, USA), Bax (2772;
Cell Signaling, Danvers, MA, USA), VDAC (PA1-954A; Cell Signaling), Actin
(ab6276; Abcam, MA, USA), TOM20 (sc-11415; Santa Cruz Biotechnology),
Cleaved caspase-3 (9661S; Cell Signaling), Cleaved PARP (9544S; Cell
Signaling), GAPDH (sc-365062; Santa Cruz Biotechnology), succinate dehydrogen-
ase complex-subunit A (SDHA) (ab14715; Abcam), Human Bax (2D2; sc-20067;
Santa Cruz Biotechnology) NdufS4 (ab55540; Abcam) and ATP5A (ab14748;
Abcam). Secondary antibodies and ECL-plus were purchased from GE Healthcare
(Piscataway, NJ, USA). Following ECL application, blots were exposed to HyBlot
Cl autoradiography ﬁlm (Denville Scientiﬁc, Metuchen, NJ, USA). Staurosporine
and CCCP were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Isolation of primary neurons and astrocytes. The isolation of primary
cortical neurons was carried out as previously described.
64 Following 3 days in
culture, neurons were treated with vehicle (DMSO), 300nM staurosporine for 1, 3
or 6h, or 10mM CCCP for 6 or 24h Astrocytes were isolated using a modiﬁed
version of the protocol previously described.
65 Brieﬂy, glia were obtained from
P1–P4 pups and plated and cultured in vitro for 15–20 days. Once the astrocyte
monolayer was conﬂuent, astrocytes were isolated from the culture using mild
trypsinization. Astrocytes were freshly plated for experiments and treated with
10mM CCCP for 6 or 24h.
Cytosolic and mitochondrial fractionation. To extract whole cell,
cytosolic and mitochondrial fractions, cells or neurons were homogenized and
mitochondria pelleted as previously described.
2 Brieﬂy, treated cells were
collected, washed in ice-cold PBS and the following isolation procedure was
carried out at 41C. A fraction of the cells were pelleted and lysed in 1% NP-40
with protein inhibitor cocktail, incubated on ice for 25min followed by centrifugation
at 6000 g for 10min to obtain soluble whole-cell lysates. For subcellular
fractions, the remainder of washed pellets was suspended in 1ml isolation buffer
(200mM sucrose, 10mM Tris/MOPS, 1mM EGTA/Tris) and lysed using 20
strokes of a Potter-Elvehjem homogenizer (Wheaton, Milville, NJ, USA). The
homogenate was then drawn with an 18.5G needle and expelled through a 27.5G
needle eight times. The homogenates were centrifuged at 200 g for 5min to
discard the nuclear pellet and debris. The remaining supernatant was centrifuged
at 10000 g for 10min to obtain the cytosolic fractions in the supernatant.
The pellet containing the heavy mitochondrial fraction was lysed in 1% NP-40 with
protein inhibitor cocktail and incubated on ice for 25min. The NP-40 insoluble
material was pelted by centrifugation at 10000 g for 5min and was discarded
and the soluble extracted mitochondrial proteins were used for analysis. All
experiments were performed in triplicate and representative images are shown.
Western blot. Cells were lysed in equal volumes of buffer containing 1%
NP-40 with protease inhibitors on ice for 25min and then centrifuged at 10000 g
for 10min. Protein assays were carried out on the supernatants using the Pierce BCA
Protein Assay kit (Thermo Scientiﬁc, Rockford, IL, USA). SDS-Laemmli buffer was
added and samples were heated at 651C for 5min. Equal concentrations of each
sample were loaded onto Novex Tris-Glycine (Invitrogen) or Criterion Tris-HCl
(Bio-Rad, Hercules, CA, USA) pre-cast gels and transferred onto polyvinylidene
ﬂuoride membranes (Millipore, Billerica, MA, USA) for Western blotting.
Immunoprecipitation. To determine the ubiquitination of Bax, HEK cells
were treated with 10mM MG-132 or vehicle (DMSO) for 6h prior to lysis. Protein
normalized lysates were pre-cleared with Protein-A agarose beads (Roche
Diagnostics, Indianapolis, IN, USA) for 2h at 41C and then IPed using a
polyclonal Bax antibody conjugated to agarose beads (sc-493AC; Santa Cruz
Biotechnology) overnight at 41C. The beads were washed 3 15min in 1 
STEN buffer (50mM Tris, pH 7.6, 150mM NaCl, 2mM EDTA, 0.2% NP-40) and
SDS-Laemmli buffer was added and samples were heated at 651C for 5min.
Given the ability of parkin to decrease Bax,
3 aliquots of each sample were ﬁrst
analyzed to determine the individual Bax IP efﬁciency, as parkin expression
decreases Bax levels. Then, elutes were normalized to equal Bax pulldown and
run alongside starting lysates on subsequent gels to examine Bax ubiquitination
(ubiquitin, 3936; Cell Signaling) using standard Western blotting conditions. Blots
were stripped in 1  stripping buffer (62.5mmol/l Tris, pH 6.8, 2% (wt/vol) SDS,
7.6% bME) at 551C for 10min, washed 3 10min in 0.1% PBS/Tween, and
probed for human Bax 2D2 to ensure pulldown.
Todetermineparkin-Baxinteractions,HEKcellsweretransientlytransfectedwith
myc-tagged WT parkin, mutant R275W or W453X parkin along with either Flag-
tagged WT Bax or domain-swapped Bax-BH3
sw. Protein normalized lysates were
incubated with myc-conjugated agarose beads (A7470; Sigma-Aldrich) overnight at
41C. The beads were washed 3 15min in 1  STEN buffer and elutes and
starting lysates were probed for Bax using Flag M2 antibody (A2220; Sigma-
Aldrich). Blots were also probed for parkin to ensure pulldown. To further evaluate
parkin-Bax interactions, CHO cells overexpressing WT human parkin (CHO-parkin)
were transiently transfected with either GFP-tagged WT Bax or K21R/K64R mutant
Bax and lysed for analysis. Protein normalized lysates were IPed using Protein-G
agarose beads (Roche Diagnostics) and a monoclonal parkin antibody (PRK8)
overnight at 41C. Beads were washed and eluted as stated earlier and run
alongside starting lysates. Lysates and elutes were probed for Bax using GFP
antibody (A11122; Invitrogen). Blots were also probed for parkin (sc-30130; Santa
Cruz Biotechnology) to ensure pulldown.
Quantitative PCR. RNA was puriﬁed from parental HEK and stably
expressing parkin (HEK-Parkin) cells using the PureLink RNA Mini Kit (Invitrogen)
from which cDNA was generated using SuperScript II Reverse Transcriptase
(Invitrogen). TaqMan qPCR was carried out for human Bax and GAPDH using
TaqMan Gene Expression Assays (Bax: 4453320 and GAPDH: 4448892;
Invitrogen) and ViiA 7 Real-Time PCR system (Life Technologies), respectively.
Imaging GFP-tagged proteins. Parental CHO cells, or those stably
expressing parkin (CHO-Parkin) or transiently transfected with WT parkin or
R275W-Parkin were grown on coverslips and transfected with WT GFP-Bax, or the
various GFP-tagged Bax mutants along with mito-mCherry to visualize
mitochondria. Twenty-four hours after transfection, cells were treated with vehicle
(DMSO) or staurosporine (1mM, 5h). Cells were ﬁxed using 4% paraformalde-
hyde, mounted onto slides and images were captured on a Zeiss Axio Imager M2
microscope (Carl Zeiss, Inc., Jena, Germany). Co-transfected cells were scored by
visually categorizing them according to localization of Bax with respect to the
mitochondrial marker mito-mCherry. They were categorized according to the
degree of co-localization with mito-mCherry as ‘completely cytosolic’, ‘predomi-
nantly cytosolic’, ‘predominantly mitochondrial’ and ‘completely mitochondrial’, and
plotted as a ratio to total cells counted. The experiments were performed in
duplicate and repeated in three biological replicates, with a minimum of 46 cells
counted per ﬁeld.
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coverslips and transiently transfected with empty vector plasmid, untagged WT
Bax, the ØK Bax or the K21R/K64R mutant Bax. Twenty-four hours after
transfection, cells were treated with vehicle (DMSO) or staurosporine (1mM, 6h).
Cells were ﬁxed with 4% paraformaldehyde, permeabilized with 0.1% Triton-X and
immunostained for human Bax 2D2 (sc-20067; Santa Cruz Biotechnology) and
stained with DAPI to visualize nuclei. Cy3-conjugated secondary antibodies were
purchased from Jackson ImmunoResearch (West Grove, PA, USA). Coverslips
were inverted onto slides and images were acquired using a Zeiss Axio Imager M2
microscope. Images were scored to quantify the different stages of Bax
translocation into the mitochondria by a blinded observer as described above. All
experiments were performed in triplicate and representative images are shown.
Statistical analysis. Quantitative translocation of Bax was compared by
one-way ANOVA followed by Tukey’s multiple comparison test. A P-value
ofo0.05 was considered signiﬁcant.
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